Health-related quality-of-life assessment in clinical trials of supportive care in oncology

Supportive Care in Cancer

Volumn 8, Issue 2, 2000, Pages 84-88

  Osoba, David ^a,b  

^a QOL Consulting   (Canada)

^b NONE   (Canada)

Author keywords

Health related quality of life; Oncology; Supportive care; Symptom control

Indexed keywords

ANOREXIA; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; VOMITING; WEIGHT REDUCTION;

EID: 0034104208     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050020     Document Type: Article

References (22)

1. Aaronson NK, Bullinger M, Ahmedzai S (1988) A modular approach to quality-of-life assessment in clinical trials. In: Scheurlen H, Kay R, Baum M (eds) Cancer clinical trials: a critical appraisal. (Recent results in cancer research, vol 111) Springer, Berlin Heidelberg New York, pp 231-249
2. Bjordal K, Kaasa S (1992) Psychometric validation of the EORTC Core Quality of Life Questionnaire, a 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 31:311-321
3. Bruera E, Khuen N, Miller MJ, et al (1991) The Edmonton symptom assessment system (ESAS): a method for the assessment of palliative care patients. J Palliat Care 7:6-9
4. Bruera E, Ernst S, Hagen N, et al (1998) Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 2:74-78
5. Cella DF, Bonomi A, Lloyd SR, et al (1995) Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220
6. Clavel M, Soukop M, Greenstreet YLA (1993) Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 50:180-185
7. De Haes JCJM, Welvart K (1985) Quality of life after breast cancer surgery. J Surg Oncol 28:123-125
8. Demetri GD, Kris M, Wade J, et al (1998) Quality-of-life benefit in patients treated with epoietin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412-3425
9. Helsing M, Bergman B, Thaning L, et al (1998) Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 34:1036-1044
10. Lindley CM, Hirsch JD, O'Neil CV, et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
11. O'Brien BJ, Rusthoven J, Rocchi A, et al (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and costs: survey of five Canadian centres. Can Med Assoc J 149:296-302
12. Osoba D (1993) Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology. Cancer Treat Rev [Suppl A] 19:43-51
13. Osoba D, Zee B, Warr D, et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307-313
14. Osoba D, Tannock IF, Ernst S, Neville J (1999) Health-related quality of life in men with metastatic prostate cancer treated by prednisone alone or mitoxantrone and prednisone. J Clin Oncol (in press)
15. Pater J, Osoba D, Zee B, et al (1998) Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual Life Res 7:273-278
16. Porter AT, McEwan AJB, Powe JE, et al (1993) Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813
17. Rowland KM Jr, Loprinzi CL, Shaw EG, et al (1996) Randomized double-blind placebo-controlled trial of cis-platin and etoposide plus megestrol acetate in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 14:135-141
18. Rusthoven JJ, Osoba D, Butts CA, et al (1998) The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 6:389-395
19. Simons JPFHA, Aaronson NK, Vansteenkiste JF, et al (1996) Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicentre study. J Clin Oncol 14:1077-1084
20. Sprangers MAG, Groenvold M, Arraras JI, et al (1996) The European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Life Questionnaire Module: first results from a three-country field study. J Clin Oncol 14:2768-2768
21. Tannock IF, Osoba D, Stockler MR, et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-64
22. Willan AR, Warr D, Pater JL, et al (1991) Methodological issues and antiemetic studies. In: Osoba D (ed) Effect of cancer on quality of life. CRC Press, Boca Raton, pp 229-249